Acute non lymphoid leukemia following CMF treatment as adjuvant therapy in positive node breast cancer. Case report.
The CMF regimen as an adjuvant therapy for breast cancer with axillary node involvement has become "standard therapy" at least for some subsets of patients (according to the Second Consensus Development Conference on Adjuvant Chemotherapy for Breast Cancer). The acute toxicity of such a regimen is usually mild and well tolerated; the late toxicity is mainly represented by amenorrhea. Here a case of acute non-lymphoid-leukemia (ANLL) after six CMF cycles is reported.
Zampa
G
G
Divisione di Medicina, Ospedale S. Giacomo, Roma, Italy.
Andriani
A
A
Beni
A
A
Patino
N
N
Rinaldi
P
P
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000139:chemically induced*; D008207:Lymphatic Metastasis; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects
D002945:Cisplatin; D005472:Fluorouracil; D008727:Methotrexate